Analytical Data
-
Gene name
AAV2gp07
- Application
-
Alternative Names
(Major coat protein VP3)
-
Species
Adeno-associated virus
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
A0A513ZUU9
-
Expression Region
1-533aa
-
Molecular Weight
64.0 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
AAV2gp07, derived from adeno-associated virus type 2 (AAV2), represents a promising avenue in gene therapy research due to its ability to deliver therapeutic genes effectively and safely. The unique properties of AAV, such as its non-pathogenic nature and capacity for long-term gene expression, make it an appealing vector for therapeutic applications. The gp07 modification enhances its tropism for specific tissues, improving delivery efficiency to targeted cells. This modification has garnered significant attention, particularly in the treatment of genetic disorders, neurodegenerative diseases, and certain cancers. Researchers are increasingly focused on understanding the structure-function relationship of AAV2gp07, optimizing its vector design, and evaluating its safety and efficacy in preclinical models. These studies aim to unlock the full potential of AAV2gp07 in clinical applications, paving the way for novel therapeutic strategies that could transform patient outcomes across various medical fields. The ongoing exploration of AAV2gp07's capabilities underscores the exciting advancements in molecular medicine, offering hope for conditions currently lacking effective treatments.
